Former colleague works for Adamas as they are beginning to build out a commercialization team. Expectations are high but, as in many similar cases, I'm not sure the company is capable of successfully launching the drug even if they get approval in August. Approval is only 1 part of the equation: See Mannkind and Afrezza.